Novartis blueprints $36M vaccine research lab in NC

Novartis ($NVS) has blueprinted plans for a $36 million vaccine research lab in Holly Springs, NC, and plans to fill about 100 high-paying jobs to staff the addition.

The expansion follows the construction of Novartis' $600 million vaccine manufacturing plant, which opened last year. This new facility will include vaccine manufacturing capacity to produce experimental vaccines for research studies.

Novartis, which landed a 167-acre site in Holly Springs, is creating a vaccine research and manufacturing hub in the area alongside Merck ($MRK) and Pfizer ($PFE).

- here's the story from the News & Observer

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.